title: Clinical efficacy and safety of cilostazol: a critical review of the literature.
abstract: Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other antiplatelet agents, cilostazol does not appear to increase the rate of bleeding. Despite the possible benefit of cilostazol, its use is limited by tolerability as some patients often report drug discontinuation due to headache, diarrhea, dizziness, or increased heart rate. To date, it has been predominantly studied in the Asian population, making it difficult to extrapolate these results to a more diverse patient population. This paper discusses the evolving role of cilostazol in the treatment of vascular diseases.
authors.affiliation: Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, 881 Madison Ave, Rm 457, Memphis, TN, 38163, USA, krogers1@uthsc.edu.
authors.forename: Kelly C
authors.initials: KC
authors.lastname: Rogers
authors.forename: Carrie S
authors.initials: CS
authors.lastname: Oliphant
authors.forename: Shannon W
authors.initials: SW
authors.lastname: Finks
mesh_terms: D000818:Animals; D000077407:Cilostazol; D006470:Hemorrhage / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D007383:Intermittent Claudication / Q000175:diagnosis / Q000188:drug therapy; D058729:Peripheral Arterial Disease / Q000175:diagnosis / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol